✉news WorldUS Politics first seen 1 d ago, last 1 d ago, peak #25
Aulos Bioscience to Present Phase 2 Lung Cancer Data at ESMO 2026
Original: Aulos Bioscience to Present Phase 2 Data for Imneskibart With Avelumab in Adenocarcinoma Non-Small Cell Lung Cancer at ESMO Congress 2026
Aulos Bioscience will present Phase 2 clinical trial data for imneskibart, used in combination with avelumab, in patients with adenocarcinoma non-small cell lung cancer at the ESMO Congress 2026. The announcement signals a key data readout for the company's oncology pipeline, with the findings likely to draw attention from investors and the cancer research community ahead of the congress.
Why now: The upcoming Phase 2 data presentation at a major oncology congress is a significant milestone for Aulos Bioscience and could influence the drug's development prospects.
Aulos BioscienceImneskibartAvelumabESMO Congress 2026
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/2116741